Mary Dibiase Sells 22,258 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase sold 22,258 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $10,016.10. Following the completion of the sale, the chief operating officer now owns 490,980 shares in the company, valued at $220,941. The trade was a 4.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

X4 Pharmaceuticals Stock Down 2.0 %

XFOR stock opened at $0.48 on Wednesday. The company has a market cap of $82.17 million, a price-to-earnings ratio of -5.35 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a twelve month low of $0.26 and a twelve month high of $1.60. The business has a 50 day moving average price of $0.55 and a two-hundred day moving average price of $0.61. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XFOR. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals during the third quarter worth $30,000. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals in the 2nd quarter valued at about $65,000. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after purchasing an additional 126,296 shares during the period. 72.03% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on XFOR shares. Stifel Nicolaus lowered their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.